Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.38 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842358 | 0.88 | CA12 (0.50) | CA1CA12CA9CA2ZDHHC20 | |
| SCHEMBL2547203 | 0.88 | CA12 (0.50) | CA1CA12CA9CA2ZDHHC20 | |
| SCHEMBL292339 | 0.88 | CA12 (0.50) | CA1CA12CA9CA2ZDHHC20 | |
| SCHEMBL4809167 | 0.88 | CA12 (0.50) | CA1CA12CA9CA2ZDHHC20 | |
| SCHEMBL293959 | 0.86 | CA12 (0.48) | CA1CA12CA9CA2ZDHHC20 | |
| SCHEMBL5198515 | 0.84 | CA1 (0.41) | CA1CA12CA9CA2 | |
| SCHEMBL5199715 | 0.82 | KDM4C (0.38) | CA1CA12CA9CA2 | |
| SCHEMBL42635 | 0.80 | CA12 (0.56) | CA1CA12CA9CA2ZDHHC20 | |
| SCHEMBL25615767 | 0.78 | GGPS1 (0.42) | CA1CA12CA9CA2GGPS1 | |
| SCHEMBL13997447 | 0.78 | GGPS1 (0.42) | CA1CA12CA9CA2GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2016-05-05 | — | — | US | disclosed |
| US-9067931-B2 | 2-heteroaryl carboxamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-7977485-B2 | 2-heteroaryl carboxamides | BAYER SCHERING PHARMA AKTIENGESELLSHAFT (DE) | 2011-07-12 | — | — | US | disclosed |
| EP-1515967-B1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
| EP-1515967-A1 | 2-HETEROARYL CARBOXAMIDES | Bayer HealthCare AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003104227-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | CA1 491/4885CA12 1231/4885CA9 3654/4885 |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | GRIN2A, CNR2, GRIN2C | CA1 491/4885CA12 1231/4885CA9 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.